Recent Finacing
Recent Raise
Actinobac Biomed develops Leukothera, a leukotoxin-derived protein therapeutic targeting LFA-1 to deplete disease-associated white blood cells for hematologic malignancies, autoimmune/inflammatory diseases, HIV and latent infections.
Focus Areas
Recent Investors
Total Raised
Funding rounds
Investors